FELBAMATE

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category Free-form
ATC N03AX10
UNII X72RBB02N8
EPA CompTox DTXSID9023041

Structure

InChI Key WKGXYQFOCVYPAC-UHFFFAOYSA-N
Smiles NC(=O)OCC(COC(N)=O)c1ccccc1
InChI
InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)

Physicochemical Descriptors

Property Name Value
Molecular Formula C11H14N2O4
Molecular Weight 238.24
AlogP 0.96
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 5.0
Polar Surface Area 104.64
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 17.0

Bioactivity

Mechanism of Action Action Reference
Glutamate [NMDA] receptor antagonist ANTAGONIST FDA ISBN PubMed
Protein: Glutamate [NMDA] receptor
Description: Glutamate receptor ionotropic, NMDA 2D
Organism : Homo sapiens
O15399 ENSG00000105464
Protein: Glutamate [NMDA] receptor
Description: Glutamate receptor ionotropic, NMDA 3B
Organism : Homo sapiens
O60391 ENSG00000116032
Protein: Glutamate [NMDA] receptor
Description: Glutamate receptor ionotropic, NMDA 1
Organism : Homo sapiens
Q05586 ENSG00000176884
Protein: Glutamate [NMDA] receptor
Description: Glutamate receptor ionotropic, NMDA 2A
Organism : Homo sapiens
Q12879 ENSG00000183454
Protein: Glutamate [NMDA] receptor
Description: Glutamate receptor ionotropic, NMDA 2B
Organism : Homo sapiens
Q13224 ENSG00000273079
Protein: Glutamate [NMDA] receptor
Description: Glutamate receptor ionotropic, NMDA 2C
Organism : Homo sapiens
Q14957 ENSG00000161509
Protein: Glutamate [NMDA] receptor
Description: Glutamate receptor ionotropic, NMDA 3A
Organism : Homo sapiens
Q8TCU5 ENSG00000198785
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Ion channel Ligand-gated ion channel Ionotropic glutamate receptor NMDA receptor
- - - - 61-90
Assay Description Organism Bioactivity Reference
Inhibition of wild type NR2B receptor expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control None 68.0 %
Inhibition of NR2B receptor ATD D101A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 83.0 %
Inhibition of NR2B receptor ATD T103A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 85.0 %
Inhibition of NR2B receptor ATD D104A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 75.0 %
Inhibition of NR2B receptor ATD E106A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 74.0 %
Inhibition of NR2B receptor ATD F176A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 84.0 %
Inhibition of NR2B receptor ATD F182A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 72.0 %
Inhibition of NR2B receptor ATD T233A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 84.0 %
Inhibition of NR2B receptor ATD K234A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 85.0 %
Inhibition of NR2B receptor ATD E236A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 83.0 %
Inhibition of NR2B receptor Pre-M1 N542A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 73.0 %
Inhibition of NR2B receptor Pre-M1 T544A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 69.0 %
Inhibition of NR2B receptor Pre-M1 S546A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 64.0 %
Inhibition of NR2B receptor Pre-M1 S548A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 76.0 %
Inhibition of NR2B receptor Pre-M1 F550A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 62.0 %
Inhibition of NR2B receptor Pre-M1 E552A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 77.0 %
Inhibition of NR2B receptor Pre-M1 S555A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 72.0 %
Inhibition of NR2B receptor Pre-M1 D557A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 75.0 %
Inhibition of NR2B receptor Pre-M1 V558A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 71.0 %
Inhibition of NR2B receptor M2 N615A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 66.0 %
Inhibition of NR2B receptor M2 N616A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 72.0 %
Inhibition of NR2B receptor M3c V640A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 71.0 %
Inhibition of NR2B receptor M3c I641A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 84.0 %
Inhibition of NR2B receptor M3c F642A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 75.0 %
Inhibition of NR2B receptor M3c L643A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 90.0 %
Inhibition of NR2B receptor M3c A644C mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 73.0 %
Inhibition of NR2B receptor M3c S645A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 85.0 %
Inhibition of NR2B receptor M3c Y646A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 74.0 %
Inhibition of NR2B receptor M3c T647A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 89.0 %
Inhibition of NR2B receptor M3c A648C mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 73.0 %
Inhibition of NR2B receptor M3c L650A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 76.0 %
Inhibition of NR2B receptor M3c A651T mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 72.0 %
Inhibition of NR2B receptor M3c A652T mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 83.0 %
Inhibition of NR2B receptor post-M3 M654A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 71.0 %
Inhibition of NR2B receptor post-M3 I655A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 76.0 %
Inhibition of NR2B receptor post-M3 Q656A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 70.0 %
Inhibition of NR2B receptor post-M3 E657A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 61.0 %
Inhibition of NR2B receptor post-M3 E658A mutant expressed in Xenopus oocytes assessed as NMDA current at 0.5 mM relative to control Homo sapiens 65.0 %
Displacement of [35S]TBPS from Wistar rat brain GABAA receptor Rattus norvegicus 95.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 4.88 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 37.11 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 7.68 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 15.31 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.17 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.01 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.05 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.01 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.17 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.05 %

Cross References

Resources Reference
ChEBI 4995
ChEMBL CHEMBL1094
DrugBank DB00949
DrugCentral 1140
FDA SRS X72RBB02N8
Human Metabolome Database HMDB0015084
Guide to Pharmacology 5473
KEGG C07501
PharmGKB PA449590
PubChem 3331
SureChEMBL SCHEMBL34947
ZINC ZINC000001530803
CONTENTS